AT-1226 / Ahead Therap - LARVOL DELTA

[VIRTUAL] Ten-year Trends in Patient Characteristics, Treatments, and Outcomes in St Elevation Mi Patients in the Us - A Report From NCDR CP-MI Registry (AHA 2020) - " Annual trends in patient characteristics and in-hospital treatments of 604,936 STEMI patients treated at 1226 US hospitals between 2009 and 2018 were analyzed... Characteristics of patients presenting with STEMI changed over time with improvements in primary PCI use and timeliness. However, there was no significant reduction in risk-adjusted mortality over the past decade."

Clinical • Atrial Fibrillation • Cardiovascular • Diabetes • Metabolic Disorders

[VIRTUAL] An Unusual Case of Acute Myocardial Infarction Revealing Underlying Polycythemia Secondary to Exogenous Bioidentical Testosterone Therapy (ENDO-I 2020) - "Lexiscan indicated anterior territory ischemia and coronary angiography revealed 95% stenosis of the left anterior descending artery (LAD)...During the patient’s workup, he was noted to have elevated hemoglobin (20) and hematocrit (60) levels and was treated with 1g hydroxyurea as phlebotomy was unavailable...Serum total testosterone was elevated at 1226 ng/dL... Considering polycythemia can arise secondary to exogenous testosterone use and is a known risk factor for cardiovascular events, it is likely this patient’s myocardial infarction was complicated by his use of exogenous bioidentical testosterone. Compound pharmacies providing bioidentical testosterone are not required to report adverse events, provide black box warnings, or show evidence-based safety and efficacy profiles for their products. The increasing availability and use of non-FDA-approved testosterone therapies warrants increased physician vigilance, particularly for patients with existing cardiac..."

Clinical • Late-breaking abstract • Cardiovascular • Diabetes • Dyslipidemia • Gene Therapies • Hypertension • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • Pain • Reperfusion Injury • Type 2 Diabetes Mellitus • JAK2

An Unusual Case of Acute Myocardial Infarction Revealing Underlying Polycythemia Secondary to Exogenous Bioidentical Testosterone Therapy (ENDO 2020) - "Lexiscan indicated anterior territory ischemia and coronary angiography revealed 95% stenosis of the left anterior descending artery (LAD)...During the patient's workup, he was noted to have elevated hemoglobin (20) and hematocrit (60) levels and was treated with 1g hydroxyurea as phlebotomy was unavailable...Serum total testosterone was elevated at 1226 ng/dL... Considering polycythemia can arise secondary to exogenous testosterone use and is a known risk factor for cardiovascular events, it is likely this patient's myocardial infarction was complicated by his use of exogenous bioidentical testosterone. Compound pharmacies providing bioidentical testosterone are not required to report adverse events, provide black box warnings, or show evidence-based safety and efficacy profiles for their products. The increasing availability and use of non-FDA-approved testosterone therapies warrants increased physician vigilance, particularly for patients with existing cardiac..."

Clinical • Late-breaking abstract • JAK2

A global streamflow reanalysis for 1980-2018. (PubMed, J Hydrol X) - "The model was calibrated at 1226 river sections with a total drainage area of 51 million km within 66 countries, using ECMWF's latest atmospheric reanalysis ERA5...In addition, observed discharges with high data quality is key to achieving skillful model output. The new calibrated model will become part of the operational runs of GloFAS in the next system release foreseen for Spring 2020, together with a near real time extension of the streamflow reanalysis."

Clinical • Journal